Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Pfizer Calls For Sustainable Approach To Ensure Viability Of Biosimilars Market

Global biosimilars player Pfizer is calling for a more sustainable approach to the market to ensure its long-term viability. In the second part of an exclusive interview, Barry Chester, the firm’s global commercial lead for supportive care oncology, tells Generics Bulletin where the company sees room for improvement.

Biosimilars Strategy

Alvotech And Stada Are Back With A Denosumab Biosimilar Deal

With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.

Deals Strategy

‘We’ve Got The Broadest Pure-Play Oncology Portfolio In The industry’ – Pfizer Talks Biosimilars

Pfizer is one of the leading players in the global biosimilars market. Barry Chester, the firm’s global commercial lead for supportive care oncology, talks to Generics Bulletin about how the business fits into the firm’s wider interests, in the first part of an exclusive interview.

Biosimilars Strategy

Lotus Builds In Southeast Asia With Teva Thailand Acquisition

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

M & A Deals
See All

Deals Explore this Topic

Set Alert for Deals

Richter Swallows Up Estetrol Franchise And More From Stricken Mithra

Gedeon Richter is looking to chart its own path in women’s healthcare and expand its global footprint, after buying up a bundle of businesses and key products and pipeline assets from Belgium’s Mithra.

M & A Deals

Alvotech And Stada Are Back With A Denosumab Biosimilar Deal

With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.

Deals Strategy

Lotus Builds In Southeast Asia With Teva Thailand Acquisition

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

M & A Deals

Viatris Waves Goodbye To API Business

Viatris has marked another milestone in its ongoing transformation by completing the previously-announced divestment of its active pharmaceutical ingredient business to Matrix Pharma Private Limited in India.

Strategy Deals
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Xbrane Welcomes Milestone In $14bn Nivolumab Journey, Partner Sought

In a for-now limited pool of chasers, Sweden’s Xbrane Biopharma has unveiled a milestone and business update for its proposed biosimilar to Bristol Myers Squibb’s major PD-1 inhibitor, Opdivo.

Biosimilars Manufacturing

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits.

Manufacturing Regulatory

Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan

US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.

Manufacturing Reimbursement

Duo Falter Again On US Belbuca ANDA, Eight Years After Joining Hands

IntelGenx has once again been frustrated in its attempts to challenge Collegium’s powerful opioid Belbuca in the US, amid ongoing litigation over the brand’s three US patents that run until December 2032. Meanwhile, Teva’s desire to push on with its own January 2027 launch has been called into question.

Complete Response Letters Generic Drugs
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Lotus Builds In Southeast Asia With Teva Thailand Acquisition

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

M & A Deals

Alkem Misses Analyst Estimates In Fourth Quarter, Lowering Future Guidance

Alkem has missed analyst estimates with its fourth quarter revenue results, which featured a domestic slump in the anti-infective segment, despite higher EBITDA margins.

BioPharmaceutical India

Aurobindo’s Eugia Prepares For ‘Muted’ Growth In FY2025

While Eugia continues to look for ways to solve the future challenges amidst temporary plant closure, parent Aurobindo reported a “good” performance in FY2024, with expected continued growth, and gave an update on its Auro Peptides business and GLP-1s.

Generic Drugs Strategy

Torrent Spells Out Ambitions For $300m Business In The US

India’s Torrent underlined that it had no plans of decreasing its commitment to the US market, while plotting continued growth in India and Germany, as it delivered financial results for its 2023/24 financial year.

Sales & Earnings Strategy
See All

People Explore this Topic

Set Alert for People

Who’s Hired? Dr Reddy’s Names New North America Chief

A busy couple of weeks for executive appointments in the generics and biosimilars industry has seen Dr Reddy’s name a new North American CEO, Fresenius Kabi appoint a new biopharma chief, Teva recruit a new head of global operations, and more.

Executive Changes Leadership

Who’s Hired? mAbxience Appoints A New CEO

Spain’s mAbxience has named a new CEO following the departure of former chief Emanuelle Lepine. Meanwhile, Biosimilars Canada has re-elected its chair and vice-chair, while Lupin has added a pair of independent directors to its board.

Executive Changes Leadership

Who’s Hired? Teva Brings New Legal Head Onboard

Generics Bulletin reports on some of the most noteworthy and important appointments affecting the global generics and biosimilar industries.

Executive Changes Companies

Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Executive Changes Leadership
See All
UsernamePublicRestriction

Register